BeOne Medicines Ltd.
ONC Nasdaq
SEC CIK 1651308
Follow BeOne Medicines Ltd.
Weekly email: filings, results
Revenue, last quarter
$1.9B
+33.8% vs same quarter last year
Net income
$384.7M
+208.2% vs same quarter last year
EPS, diluted
$0.25
+212.5% vs same quarter last year
Operating cash flow
$508.7M
+26.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $5.3B | $286.9M |
| FY24 | $3.8B | −$644.8M |
| FY23 | $2.5B | −$881.7M |
| FY22 | $1.4B | −$2B |
| FY21 | $1.2B | −$1.5B |
| FY20 | $308.9M | −$1.6B |
| FY19 | $428.2M | −$948.6M |
| FY18 | $198.2M | −$673.8M |
| FY17 | $238.4M | −$93.1M |
| FY16 | $1.1M | −$119.2M |
| FY15 | $8.8M | −$57.1M |
| FY14 | $13M | −$18.3M |
| FY13 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.5% | 8.4% | 5.4% |
| FY24 | 84.4% | −14.9% | −16.9% |
| FY23 | 84.5% | −49.1% | −35.9% |
| FY22 | 79.8% | −126.4% | −141.5% |
| FY21 | 86% | −122.3% | −123.9% |
| FY20 | 77.1% | −536.7% | −526.1% |
| FY19 | 83.4% | −224.2% | −221.5% |
| FY18 | 85.5% | −356.1% | −339.9% |
| FY17 | 97.9% | −41.3% | −39.1% |
| FY16 | 100% | −10940.2% | −11141.8% |
| FY15 | - | −643.7% | −647.7% |
| FY14 | - | −120.9% | −140.2% |
| FY13 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $941.7M |
| FY24 | −$633.3M |
| FY23 | −$1.7B |
| FY22 | −$1.8B |
| FY21 | −$1.6B |
| FY20 | −$1.4B |
| FY19 | −$839.9M |
| FY18 | −$618M |
| FY17 | −$33.6M |
| FY16 | −$113M |
| FY15 | −$45.2M |
| FY14 | −$9.3M |
| FY13 | - |
- BeOne Medicines Ltd.
- Healthcare median
Show the numbers
| Year | BeOne Medicines Ltd. | Healthcare median |
|---|---|---|
| FY25 | 5.4% | −30.6% |
| FY24 | −16.9% | −47% |
| FY23 | −35.9% | −58% |
| FY22 | −141.5% | −80.4% |
| FY21 | −123.9% | −71.9% |
| FY20 | −526.1% | −62.2% |
| FY19 | −221.5% | −46.3% |
| FY18 | −339.9% | −49.6% |
| FY17 | −39.1% | −45.9% |
| FY16 | −11141.8% | −36% |
| FY15 | −647.7% | −38.4% |
| FY14 | −140.2% | −35.5% |
| FY13 | - | −37.1% |